BIOVIE INC
BIOVIE INC logo
BIVI

BIOVIE INC (BIVI)

$8.0519.44%

Market is closed
– opens on 8 PM, 02 Dec 2022
  • $

1D

1W

1M

1Y

3Y

5Y

Key Stats

$6.5664
Day's Range
$8.2
$1.33
52-Week Range
$8.255
1 month return101.75%
3 month return186.48%
1 year return39.27%
5 year return19.42%

Company Information

BioVie Inc. is developing BIV201 (continuous infusion terlipressin) an Orphan Drug candidate for the treatment of ascites due to advanced liver cirrhosis. First-to-market Orphan therapies typically receive 7 years of market exclusivity in the US for the designated use(s). It is being investigated as a potential new therapy for patients suffering from ascites, and future development opportunities include hepatorenal syndrome (HRS) and other life-threatening complications of advanced liver cirrhosis. The initial disease target for BIV201 therapy is ascites, which is a serious complication of advanced liver cirrhosis. The Company has completed a Phase 2 clinical trial protocol that is summarized on www.clinicaltrials.gov, trial identifier NCT04112199. The FDA has never approved any drug specifically for treating ascites, and the Company is not aware of any competing drugs in late-stage development for ascites. The active agent in BIV201, terlipressin, is approved for use in about 40 countries for the treatment of related complications of advanced liver cirrhosis but is not available in the US or Japan. The Company has invented a patent-pending prefilled syringe that has been cleared for use in our upcoming Phase 2 trial subject to certain additional standard analytical tests. This novel BIV201 delivery system is expected to greatly simplify at-home patient treatment and improve patient compliance by enabling easy injection of the liquid concentrate into the IV bag connected to the infusion pump. Room temperature stability has been achieved for 9 months providing an important advantage because, to the best of the Company's knowledge, all other terlipressin products sold globally must be stored under refrigeration. The novel prefilled syringe format also avoids the manual mixing of minute (2 - 4 mg) quantities of terlipressin powder in saline solution, thereby reducing the possibility of dosing errors during reconstitution and improving sterility. BioVie has begun applying for global patent protection for this novel terlipressin delivery system. The Company has also received Orphan Drug designation for the treatment of hepatorenal syndrome (HRS) and has FDA Fast Track status.
OrganizationBIOVIE INC
Employees13
CEOMr. Cuong Viet Do M.B.A., MBA
IndustryBiotechnology

Analyst Recommendation

based on 1 analysts ratings

Buy
100%
Buy
0%
Hold
0%
Sell

Based on 1 Wall street analysts offering stock ratings for BIOVIE INC(by analysts ranked 0 to 5 stars)

Analyst Forecast

What analysts predicted

Upside of 11.8%

Current

$8.05

Target

$9.0

Recommendation Trend

Based on 1 analyst

Current1M Ago3M Ago
Buy
1
9
9
Hold
0
1
1
Sell
0
0
0
Consensus
BUY
BUY
BUY

Highlights

Market Capitalization
245.8M
Book Value
$0.2
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-6.68
Wall Street Target Price
9.0

Valuation

Trailing PE0.0
Forward PE0.0
Price/Book (mrq)
33.86
Enterprise Value
193.4M
Enterprise Value/Revenue
0.0
Enterprise Value/Ebitda
-7.03

Technicals

Beta
2.67
50 Day MA
3.87
200 Day MA
3.13

Institutional Holdings

Sabby Management LLC

2.08%

swisspartners Ltd.

0.53%

Geode Capital Management, LLC

0.13%

Vanguard Group Inc

0.12%

Kepos Capital LP

0.08%

Long Focus Capital Management, LLC

0.07%

Discover more

Frequently Asked Questions

What is BIOVIE INC share price today?

Can Indians buy BIOVIE INC shares?

How can I buy BIOVIE INC shares from India?

Can Fractional shares of BIOVIE INC be purchased?

What are the documents required to start investing in BIOVIE INC stocks?

What are today’s High and Low prices of BIOVIE INC?

What are today’s traded volumes of BIOVIE INC?

What is today’s market capitalisation of BIOVIE INC?

What is the 52 Week High and Low Range of BIOVIE INC?

How much percentage BIOVIE INC is down from its 52 Week High?

How much percentage BIOVIE INC is up from its 52 Week low?

What are the historical returns of BIOVIE INC?

Who is the Chief Executive Officer (CEO) of BIOVIE INC?

Trading and brokerage services provided by

Banking and Remittance services provided by

Technology services provided by : Finzoomers Services Private Limited

Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*